Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 10/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451382 | 0.92 | TACR1 (0.49) | ALDH1A1LMNAGAATSHRTACR1 | |
| SCHEMBL14007668 | 0.90 | CYP2C19 (0.55) | CYP2C19ALDH1A1LMNAGAATSHR | |
| SCHEMBL15077173 | 0.81 | TACR1 (0.46) | TACR1IDO1 | |
| SCHEMBL15078647 | 0.81 | TACR1 (0.41) | ALDH1A1LMNAGAATSHRTACR1 | |
| SCHEMBL10104524 | 0.81 | TACR1 (0.41) | ALDH1A1LMNAGAATSHRTACR1 | |
| SCHEMBL13178016 | 0.79 | TACR1 (0.61) | TACR1IDO1SERPINE1 | |
| SCHEMBL788092 | 0.79 | TACR1 (0.40) | ALDH1A1LMNAGAATSHRTACR1 | |
| SCHEMBL12305670 | 0.79 | ALDH1A1 (0.46) | CYP2C19ALDH1A1LMNAGAATSHR | |
| SCHEMBL30950869 | 0.79 | TACR1 (0.40) | ALDH1A1LMNAGAATSHRTACR1 | |
| SCHEMBL345830 | 0.79 | SLC6A4 (0.43) | ALDH1A1LMNAGAATSHRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | CYP2C19 1695/4885ALDH1A1 1886/4885LMNA 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.